U.S. Capital Investment into the EU’s Cannabis Industry: A New Era
The recent recommendation by the U.S. Department of Health and Human Services (HHS) to reschedule cannabis from a Schedule I to a Schedule III substance under the Controlled Substances Act marks a pivotal shift for the cannabis industry globally. This rescheduling not only signifies a significant step in changing the perception of cannabis in the […]
U.S. Capital Investment into the EU’s Cannabis Industry: A New Era Read More »
